Press Releases

Angel Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, today announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to initiate a Phase 1/1b clinical trial in China. Angel Pharma owns mupadolimab's rights in Greater China. Mupadolimab is a humanized monoclonal antibody directed against CD73 . In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of ly

With cases of monkeypox continuing to rise and spread around the world, government health departments are providing advice and guidance on how to help prevent transmission of the disease with hygiene and disinfection of the utmost importance. The high level disinfectant Rely+On Virkon from specialty chemicals company LANXESS is effective against the monkeypox virus. The product is used for hard surface disinfection in hospital, healthcare and institutional facilities, airports, publ

Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company focused on introducing innovative long-acting depot injectable products, announced today positive top-line results from the GA Depot (a long acting glatiramer acetate) Phase III clinical trial assessing the efficacy, safety and tolerability of a once monthly GA Depot 40 mg compared to placebo in relapsing forms of multiple sclerosis (RMS) patients. Top-line efficacy results showed that GA Depot 40 mg

GSK and Spero Therapeutics, Inc. announced they have entered into an exclusive license agreement for Spero’s late-stage antibiotic asset, tebipenem HBr. Tebipenem HBr is being developed as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria. Luke Miels, Chief Commercial Officer, GSK said, “There is a high unmet medical need for a novel oral antibiotic as an alternative

This two-day event was held on September 15th and 16th.It was a uniquely planned event, where the focus was on understanding how organisations can build an apt strategy for achieving manufacturing excellence and using digital and automation as tools for modernising. The conference ensured continuous engagement of the audience & speakers through various discussions in the form of Case-Study solving, Panel Discussion and group discussions to understand and create a viable Business

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the presentation of data from the Boehringer Ingelheim-sponsored Phase 2 clinical trial of BI 456906, a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in patients with type 2 diabetes at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) being held in Stockholm September 19 – 23, 2022.

Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, entered into an agreement with TCG GreenChem, Inc. to manufacture Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in formulating the drug product for testing in clinical trials of Ropidoxuridine and RT of cancers. "Shu

A compact, affordable microfluidic system for custom microfluidic and genomics research is launching September 21st. This new system from Dolomite Bio, combines the microfluidic technology underlying their Nadia Instrument, with the customisable parameters of the Nadia Innovate, granting access to the custom microfluidic protocol development without the necessity of large capital outlay. Currently most custom microfluidic research is performed using older complex modular systems. Th

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, today announces its complete acquisition of India-based excipient manufacturer, Crest Cellulose. Following its purchase of a majority share in the company in 2018, this latest move allows Roquette to continue realizing its strong growth ambitions and meet rising global demand for high-quality plant-based excipients. Thanks to this wholly owned subsidiary, Roquette’

Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Mycapssa® in the European Union (EU) for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or